These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

586 related articles for article (PubMed ID: 28658986)

  • 1. Ocrelizumab: a B-cell depleting therapy for multiple sclerosis.
    Jakimovski D; Weinstock-Guttman B; Ramanathan M; Kolb C; Hojnacki D; Minagar A; Zivadinov R
    Expert Opin Biol Ther; 2017 Sep; 17(9):1163-1172. PubMed ID: 28658986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ocrelizumab Depletes CD20⁺ T Cells in Multiple Sclerosis Patients.
    Gingele S; Jacobus TL; Konen FF; Hümmert MW; Sühs KW; Schwenkenbecher P; Ahlbrecht J; Möhn N; Müschen LH; Bönig L; Alvermann S; Schmidt RE; Stangel M; Jacobs R; Skripuletz T
    Cells; 2018 Dec; 8(1):. PubMed ID: 30597851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ocrelizumab for the treatment of multiple sclerosis.
    Bigaut K; De Seze J; Collongues N
    Expert Rev Neurother; 2019 Feb; 19(2):97-108. PubMed ID: 30570368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocrelizumab and Other CD20
    Gelfand JM; Cree BAC; Hauser SL
    Neurotherapeutics; 2017 Oct; 14(4):835-841. PubMed ID: 28695471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocrelizumab: its efficacy and safety in multiple sclerosis.
    Juanatey A; Blanco-Garcia L; Tellez N
    Rev Neurol; 2018 Jun; 66(12):423-433. PubMed ID: 29897610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B cell depletion in the treatment of multiple sclerosis.
    Myhr KM; Torkildsen Ø; Lossius A; Bø L; Holmøy T
    Expert Opin Biol Ther; 2019 Mar; 19(3):261-271. PubMed ID: 30632834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20-Yet Progress Continues.
    Frisch ES; Pretzsch R; Weber MS
    Neurotherapeutics; 2021 Jul; 18(3):1602-1622. PubMed ID: 33880738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ocrelizumab: A New B-cell Therapy for Relapsing Remitting and Primary Progressive Multiple Sclerosis.
    Stahnke AM; Holt KM
    Ann Pharmacother; 2018 May; 52(5):473-483. PubMed ID: 29232960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ocrelizumab (Ocrevus) for MS.
    Med Lett Drugs Ther; 2017 Jun; 59(1523):98-101. PubMed ID: 28609424
    [No Abstract]   [Full Text] [Related]  

  • 10. Ocrelizumab: A Review in Multiple Sclerosis.
    Lamb YN
    Drugs; 2022 Feb; 82(3):323-334. PubMed ID: 35192158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population.
    Fernandez-Diaz E; Perez-Vicente JA; Villaverde-Gonzalez R; Berenguer-Ruiz L; Candeliere Merlicco A; Martinez-Navarro ML; Gracia Gil J; Romero-Sanchez CM; Alfaro-Saez A; Diaz I; Gimenez-Martinez J; Mendez-Miralles MA; Millan-Pascual J; Jimenez-Pancho J; Mola S; Sempere AP
    Ann Clin Transl Neurol; 2021 Feb; 8(2):385-394. PubMed ID: 33369288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
    Hersh CM; Cohen JA
    Immunotherapy; 2014; 6(3):249-59. PubMed ID: 24762071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts - the CONFIDENCE study protocol.
    Dirks P; Zingler V; Leemhuis J; Berthold H; Hieke-Schulz S; Wormser D; Ziemssen T
    BMC Neurol; 2020 Mar; 20(1):95. PubMed ID: 32171264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B cell-directed therapies in multiple sclerosis.
    Gasperi C; Stüve O; Hemmer B
    Neurodegener Dis Manag; 2016; 6(1):37-47. PubMed ID: 26782316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
    Hauser SL; Bar-Or A; Comi G; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Montalban X; Rammohan KW; Selmaj K; Traboulsee A; Wolinsky JS; Arnold DL; Klingelschmitt G; Masterman D; Fontoura P; Belachew S; Chin P; Mairon N; Garren H; Kappos L;
    N Engl J Med; 2017 Jan; 376(3):221-234. PubMed ID: 28002679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world effectiveness, safety and immunogenicity of ocrelizumab in turkish multiple sclerosis patients: a single-center experience for 4-year follow-up.
    Erdogan T; Cansu C; Kocer B; Akkaya S; Kokmen H
    Acta Neurol Belg; 2024 Aug; 124(4):1385-1391. PubMed ID: 38769274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis.
    Menge T; Dubey D; Warnke C; Hartung HP; Stüve O
    Expert Rev Neurother; 2016 Oct; 16(10):1131-9. PubMed ID: 27552111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
    Montalban X; Hauser SL; Kappos L; Arnold DL; Bar-Or A; Comi G; de Seze J; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Rammohan KW; Selmaj K; Traboulsee A; Sauter A; Masterman D; Fontoura P; Belachew S; Garren H; Mairon N; Chin P; Wolinsky JS;
    N Engl J Med; 2017 Jan; 376(3):209-220. PubMed ID: 28002688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness.
    Barun B; Gabelić T; Adamec I; Babić A; Lalić H; Batinić D; Krbot Skorić M; Habek M
    Mult Scler Relat Disord; 2021 Feb; 48():102704. PubMed ID: 33370649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two cases of meningitis associated with ocrelizumab therapy.
    Theriault M; Solomon AJ
    Mult Scler Relat Disord; 2020 Feb; 38():101866. PubMed ID: 31821962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.